title: The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
abstract: Tapentadol is a novel, centrally-acting analgesic drug, with an analgesic efficacy comparable to that of strong opioids such as oxycodone and morphine. Its high efficacy has been demonstrated in a range of animal models of acute and chronic, nociceptive, inflammatory, and neuropathic pain as well as in clinical studies with moderate to severe pain arising from a number of different etiologies. At the same time, a favorable gastrointestinal tolerability has been demonstrated in rodents and humans, and advantages over morphine regarding tolerance development and physical dependence were shown in animal studies. Furthermore, a low level of abuse and diversion is beginning to emerge from first post-marketing data. Tapentadol acts as a μ-opioid receptor (MOR) agonist and noradrenaline reuptake inhibitor (NRI). Both mechanisms of action have been shown to contribute to the analgesic activity of tapentadol and to produce analgesia in a synergistic manner, such that relatively moderate activity at the two target sites (MOR and noradrenaline reuptake transporter) is sufficient to produce strong analgesic effects. It has been suggested that tapentadol is the first representative of a proposed new class of analgesics, MOR-NRI. This review presents the evidence that has led to this suggestion, and outlines how the pharmacology of tapentadol can explain its broad analgesic activity profile and high analgesic potency as well as its favorable tolerability.
authors.affiliation: Grünenthal GmbH, Grünenthal Innovation, Global Preclinical Research and Development, Zieglerstrasse 6, 52078, Aachen, Germany, thomas.tzschentke@grunenthal.com.
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Tzschentke
authors.forename: Thomas
authors.initials: T
authors.lastname: Christoph
authors.forename: Babette Y
authors.initials: BY
authors.lastname: Kögel
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage*; D000698:Analgesia / Q000379:methods*; D000818:Animals; D004359:Drug Therapy, Combination; D006801:Humans; D010146:Pain / Q000175:diagnosis / Q000188:drug therapy*; D010636:Phenols / Q000008:administration & dosage*; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000502:physiology; D000077432:Tapentadol
chemical_list: D018759:Adrenergic Uptake Inhibitors; D010636:Phenols; D017450:Receptors, Opioid, mu; D000077432:Tapentadol